Global Reach FibroScan is already deployed in 100+ countries and is expanding in the US through partnerships like United Digestive, creating sales opportunities with GI clinics, hospitals, and ambulatory centers for equipment, service contracts, and clinician training.

Evidence Advantage With over 4200 peer‑reviewed publications and 180 international guidelines, FibroScan is positioned as the non invasive gold standard, enabling conversations with hospitals, research centers, and pharma companies for NAFLD/NASH patient identification and monitoring.

LHM Growth The Liver Health Management platform opens a scalable upsell path for health systems to centralize liver care, enabling integrations with EHRs, data analytics, remote monitoring, and bundled services that can be sold to clinics and larger networks.

Strategic Partnerships Recent collaborations with gastro networks and pharma engagement for NAFLD/NASH patient workflows highlight channels for co marketing, regional expansion, and joint studies, while leadership changes in 2026 may accelerate strategic sales initiatives.

Financial Upside With a solid revenue base and a global footprint, opportunities exist to grow US market penetration, secure renewal deals, and provide training and education services to support adoption among clinicians and patients.